DMIC
BIO icon

Dixon Mitchell Investment Counsel’s Bio-Rad Laboratories Class A BIO Stock Holding History

Dixon Mitchell Investment Counsel’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$107K Sell
366
-183
-33% -$51.9K ﹤0.01% 101
2026
Q1 		$153K Hold
549
– – 0.01% 90
2025
Q4 		$166K Buy
+549
New +$171K 0.01% 86

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Dixon Mitchell Investment Counsel's BIO Position: Q2 2026 in Review

Dixon Mitchell Investment Counsel reduced its Bio-Rad Laboratories Class A (BIO) stake by 33% in Q2 2026, selling an estimated $51.9K and leaving 366 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #101.

Dixon Mitchell Investment Counsel first reported a position in BIO in Q4 2025 and has held it in 3 quarters since. The position peaked at $166K in Q4 2025. 399 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Dixon Mitchell Investment Counsel held 366 shares of Bio-Rad Laboratories Class A worth $107K as of Q2 2026.
  • Dixon Mitchell Investment Counsel sold 183 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $51.9K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Dixon Mitchell Investment Counsel's portfolio in Q2 2026, its #101 holding.
  • Dixon Mitchell Investment Counsel first reported a position in Bio-Rad Laboratories Class A in Q4 2025 and has held it in 3 quarters since.
  • Dixon Mitchell Investment Counsel's Bio-Rad Laboratories Class A position peaked at $166K in Q4 2025.
  • 399 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Dixon Mitchell Investment Counsel's 13F filing for Q2 2026, filed 13 Aug 2026.